Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christine Carlson Rahn

Family Medicine Omaha, NE Medical Doctor

NPI 1114292281 CMS profile 1296116

17675 Welch Plz, Omaha, NE 68135

Open in the dashboard

General payments

$10,156

720 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Carlson Rahn of Omaha, NE is reported in the CMS Open Payments database as having received $10,156 across 720 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,744 120
2024 General $1,715 115
2023 General $1,288 81
2022 General $1,349 97
2021 General $1,455 105
2020 General $1,006 66
2019 General $1,599 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Carlson Rahn
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Christine Carlson Rahn were reported at $1,744. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Christine Carlson Rahn Family Medicine median Middle half National median
2019 $1,599 $150 $41–$543 $163
2020 $1,006 $120 $32–$415 $114
2021 $1,455 $137 $35–$551 $132
2022 $1,349 $137 $37–$512 $149
2023 $1,288 $149 $42–$545 $160
2024 $1,715 $156 $44–$560 $164
2025 $1,744 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,242 152 payments
  2. Amgen Inc. $973 78 payments
  3. Lilly USA, LLC $908 82 payments
  4. Novo Nordisk Inc $811 66 payments
  5. AstraZeneca Pharmaceuticals LP $792 35 payments
  6. Pfizer Inc. $631 47 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $435 30 payments
  8. Janssen Pharmaceuticals, Inc $422 28 payments
  9. Allergan Inc. $304 29 payments
  10. Merck Sharp & Dohme Corporation $266 25 payments
  11. Other $2,372 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,156 720 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,157 76 payments
  2. QULIPTA $643 40 payments
  3. VRAYLAR $636 43 payments
  4. Repatha $579 49 payments
  5. Ozempic $522 43 payments
  6. FARXIGA $479 14 payments
  7. RYBELSUS $419 30 payments
  8. Otezla $391 35 payments
  9. NURTEC ODT $376 25 payments
  10. AIMOVIG $348 28 payments
  11. Other $8,699 624 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

3,186

Median for Family Practice: 1,826

Drug cost

$209,077

Median for Family Practice: $120,094

Branded share of claims

13.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 56 $59,429
Mounjaro Tirzepatide Brand 28 $40,418
Eliquis Apixaban Brand 18 $22,054
Jardiance Empagliflozin Brand 32 $21,110
Farxiga Dapagliflozin Propanediol Brand 14 $17,984
Tresiba Flextouch U-200 Insulin Degludec Brand 21 $7,900
Nebivolol Hcl Generic 14 $3,421
Omeprazole Generic 166 $2,609
Esomeprazole Magnesium Generic 15 $2,236
Gabapentin Generic 130 $2,016

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$97,769

Of which drugs: $42,004

Medicare patients

144

Average age 72

Services billed

3,158

117 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 38%
Osteoporosis 25%
Chronic kidney disease 22%
Depression 22%
Diabetes 17%
Ischemic heart disease 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 17 1,740 $35,024
Pcv20 vaccine im 90677 Office 11 11 $3,195
Vaccine for influenza for injection into muscle 90662 Office 26 26 $2,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $209
$209 — —
QULIPTA
  • AbbVie, Inc. $108
$108 — —
UBRELVY
  • AbbVie, Inc. $86
$86 — —
MOUNJARO
  • Lilly USA, LLC $75
$75 28 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $70
$70 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

720 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record